Ascend’s poly-mannose polymer platform can preferentially deliver a variety of different types of biological and small molecule payloads to myeloid cells within the tumour microenvironment. This platform has also been shown to be able to efficiently transfect DNA expression vectors or mRNA into cells that express receptors for poly-mannose.
Payloads that have been evaluated:
Mannan polymer binding to CD209+ and CD206+ myeloid cells
Ascend’s poly-mannose targeting platform can preferentially deliver antigens and/or immunotherapeutic payloads to myeloid cells that express poly-mannose binding receptors. This platform can co-deliver chemical and or genetic payloads along with a targeted vaccine antigen. These payloads can comprise small molecule chemical adjuvants such as TLR-7/8 agonists or genes encoding immune modulators and checkpoint inhibitors/agonist.
An important feature of the targeting platform is its ability to elicit cross presentation and generate a strong cytotoxic CD8+ T cell response, in addition to a strong antibody response against payload antigens. Many alternate vaccine platforms preferentially generate one or two of these responses rather than all three.